education
Download App
Indonesia
search
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Country
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
search
UserName
Profession
Email
Account
Manage Account
Change Password
Sign Out
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Other Services
Education
Download App
Country
Indonesia
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
Account
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Iklan
Iklan
MIMS home
Drugs
Info
Lapikot Forte
Lapikot Forte
sulfamethoxazole + trimethoprim
Manufacturer:
Lapi
SELECT
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Contents
Co-trimoxazole: Trimethoprim 160 mg, sulfamethoxazole 800 mg
Indications/Uses
Infections of resp, genitourinary, GI & urinary tracts, skin & ENT.
Dosage/Direction for Use
Adult
1 Forte caplet.
Childn 6-12 yr
¼-½ adult dose,
2-6 yr
¼ adult dose. To be taken 2 times daily.
Administration
Should be taken with food: Take immediately after meals.
Contraindications
Marked liver parenchymal damage. Severe renal impairment. Pregnancy.
Special Precautions
Kidney function or haematologic disorders.
Adverse Reactions
GI disturbance; SJS & Lyell's syndrome. Rarely hepatitis, blood disorders, pseudomembranous colitis.
View
ADR Reporting Link
Drug Interactions
Warfarin, phenytoin, pyrimethamine, thiazides.
MIMS Class
Antibacterial Combinations
ATC Classification
J01EE01 - sulfamethoxazole and trimethoprim ; Belongs to the class of combinations of sulfonamides and trimethoprim, including derivatives. Used in the systemic treatment of infections.
Regulatory Classification
K
Presentation/Packing
Form
Lapikot Forte caplet
Packing/Price
10 × 10's (Rp75,000/boks)
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk